| Application number | Title of the application | Filing Date | Status |
|---|
Array
(
[id] => 20555269
[patent_doc_number] => 20260055049
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-02-26
[patent_title] => CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USE
[patent_app_type] => utility
[patent_app_number] => 19/322234
[patent_app_country] => US
[patent_app_date] => 2025-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7329
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 146
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19322234
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/322234 | CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USE | Sep 7, 2025 | Pending |
Array
(
[id] => 20465353
[patent_doc_number] => 12521382
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-13
[patent_title] => 3-(hydroxy)-pyridin-4(1H)-one compounds and methods of making and using the same
[patent_app_type] => utility
[patent_app_number] => 19/202501
[patent_app_country] => US
[patent_app_date] => 2025-05-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 18
[patent_no_of_words] => 11243
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19202501
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/202501 | 3-(hydroxy)-pyridin-4(1H)-one compounds and methods of making and using the same | May 7, 2025 | Issued |
Array
(
[id] => 19816655
[patent_doc_number] => 20250074862
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-06
[patent_title] => CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USE
[patent_app_type] => utility
[patent_app_number] => 18/948050
[patent_app_country] => US
[patent_app_date] => 2024-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11630
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18948050
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/948050 | Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use | Nov 13, 2024 | Issued |
Array
(
[id] => 19656851
[patent_doc_number] => 20240423916
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-26
[patent_title] => ENCOCHLEATED ANTIFUNGAL COMPOUNDS FOR CENTRAL NERVOUS SYSTEM DELIVERY AND TREATMENT OF CRYPTOCOCCUS INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 18/767226
[patent_app_country] => US
[patent_app_date] => 2024-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10316
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18767226
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/767226 | ENCOCHLEATED ANTIFUNGAL COMPOUNDS FOR CENTRAL NERVOUS SYSTEM DELIVERY AND TREATMENT OF CRYPTOCOCCUS INFECTIONS | Jul 8, 2024 | Pending |
Array
(
[id] => 19656135
[patent_doc_number] => 20240423200
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-26
[patent_title] => FOAMING COMPOSITIONS FOR CONTROLLING ARTHROPODS
[patent_app_type] => utility
[patent_app_number] => 18/748207
[patent_app_country] => US
[patent_app_date] => 2024-06-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16839
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 163
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18748207
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/748207 | FOAMING COMPOSITIONS FOR CONTROLLING ARTHROPODS | Jun 19, 2024 | Pending |
Array
(
[id] => 19707715
[patent_doc_number] => 20250017857
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-16
[patent_title] => POLY(OXAZOLINE) CONJUGATES WITH PENDANT CATIONIC GROUPS AND LIPID NANOPARTICLES AND POLYPLEXES INCLUDING SAME
[patent_app_type] => utility
[patent_app_number] => 18/743721
[patent_app_country] => US
[patent_app_date] => 2024-06-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25650
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18743721
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/743721 | POLY(OXAZOLINE) CONJUGATES WITH PENDANT CATIONIC GROUPS AND LIPID NANOPARTICLES AND POLYPLEXES INCLUDING SAME | Jun 13, 2024 | Pending |
Array
(
[id] => 19629563
[patent_doc_number] => 20240408012
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-12
[patent_title] => LIPOSOMAL COMPOSITIONS AND METHODS OF USE THEREOF FOR IMPROVED STABILITY, BIOAVAILABILITY & SUSTAINED RELEASE
[patent_app_type] => utility
[patent_app_number] => 18/736168
[patent_app_country] => US
[patent_app_date] => 2024-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9454
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18736168
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/736168 | LIPOSOMAL COMPOSITIONS AND METHODS OF USE THEREOF FOR IMPROVED STABILITY, BIOAVAILABILITY & SUSTAINED RELEASE | Jun 5, 2024 | Pending |
Array
(
[id] => 19752759
[patent_doc_number] => 20250041324
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-06
[patent_title] => CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING
[patent_app_type] => utility
[patent_app_number] => 18/734176
[patent_app_country] => US
[patent_app_date] => 2024-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25326
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18734176
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/734176 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | Jun 4, 2024 | Pending |
Array
(
[id] => 19884095
[patent_doc_number] => 12269787
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2025-04-08
[patent_title] => Method to selectively produce benzalaniline from a Schiff-base reaction involving aniline and benzaldehyde
[patent_app_type] => utility
[patent_app_number] => 18/668526
[patent_app_country] => US
[patent_app_date] => 2024-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 3534
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18668526
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/668526 | Method to selectively produce benzalaniline from a Schiff-base reaction involving aniline and benzaldehyde | May 19, 2024 | Issued |
Array
(
[id] => 19792238
[patent_doc_number] => 12233161
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2025-02-25
[patent_title] => Lipids and lipid nanoparticle formulations
[patent_app_type] => utility
[patent_app_number] => 18/669214
[patent_app_country] => US
[patent_app_date] => 2024-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43405
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 136
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18669214
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/669214 | Lipids and lipid nanoparticle formulations | May 19, 2024 | Issued |
Array
(
[id] => 19477365
[patent_doc_number] => 20240325407
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-03
[patent_title] => METHODS AND COMPOSITIONS FOR POTENTIATING THE ACTION OF OPIOID ANALGESICS USING IBOGA ALKALOIDS
[patent_app_type] => utility
[patent_app_number] => 18/666388
[patent_app_country] => US
[patent_app_date] => 2024-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36246
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18666388
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/666388 | METHODS AND COMPOSITIONS FOR POTENTIATING THE ACTION OF OPIOID ANALGESICS USING IBOGA ALKALOIDS | May 15, 2024 | Pending |
Array
(
[id] => 19629564
[patent_doc_number] => 20240408013
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-12
[patent_title] => CNS DELIVERY OF MRNA AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/664925
[patent_app_country] => US
[patent_app_date] => 2024-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19309
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18664925
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/664925 | CNS DELIVERY OF MRNA AND USES THEREOF | May 14, 2024 | Pending |
Array
(
[id] => 19744055
[patent_doc_number] => 20250032620
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-30
[patent_title] => Formulated and/or Co-Formulated Nanocarrier Compositions Containing TFGss Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof
[patent_app_type] => utility
[patent_app_number] => 18/831041
[patent_app_country] => US
[patent_app_date] => 2024-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28415
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18831041
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/831041 | Formulated and/or Co-Formulated Nanocarrier Compositions Containing TFGss Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | May 12, 2024 | Pending |
Array
(
[id] => 19642857
[patent_doc_number] => 20240417377
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-19
[patent_title] => COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ss-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA
[patent_app_type] => utility
[patent_app_number] => 18/659997
[patent_app_country] => US
[patent_app_date] => 2024-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27296
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18659997
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/659997 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ss-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | May 8, 2024 | Abandoned |
| 18/706443 | GEL COMPOSITION, THE PREPARATION METHOD AND THE USE OF THE SAME | Apr 30, 2024 | Pending |
Array
(
[id] => 19921666
[patent_doc_number] => 12295925
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-13
[patent_title] => Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib
[patent_app_type] => utility
[patent_app_number] => 18/648426
[patent_app_country] => US
[patent_app_date] => 2024-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6683
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18648426
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/648426 | Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib | Apr 27, 2024 | Issued |
Array
(
[id] => 19938849
[patent_doc_number] => 12310962
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-27
[patent_title] => Methods and compositions for treating cancer
[patent_app_type] => utility
[patent_app_number] => 18/647511
[patent_app_country] => US
[patent_app_date] => 2024-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 7
[patent_no_of_words] => 2350
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18647511
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/647511 | Methods and compositions for treating cancer | Apr 25, 2024 | Issued |
Array
(
[id] => 19860659
[patent_doc_number] => 20250099445
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-27
[patent_title] => METHODS OF TREATMENT OF TUBEROUS SCLEROSIS COMPLEX
[patent_app_type] => utility
[patent_app_number] => 18/641640
[patent_app_country] => US
[patent_app_date] => 2024-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12419
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18641640
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/641640 | METHODS OF TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Apr 21, 2024 | Pending |
Array
(
[id] => 19948335
[patent_doc_number] => 12319682
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-03
[patent_title] => Indole and benzimidazole derivatives as dual 5-HT
[patent_app_type] => utility
[patent_app_number] => 18/637083
[patent_app_country] => US
[patent_app_date] => 2024-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15489
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18637083
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/637083 | Indole and benzimidazole derivatives as dual 5-HT | Apr 15, 2024 | Issued |
Array
(
[id] => 20634413
[patent_doc_number] => 12595280
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-04-07
[patent_title] => Phosphoramidates for the treatment of hepatitis B virus
[patent_app_type] => utility
[patent_app_number] => 18/632908
[patent_app_country] => US
[patent_app_date] => 2024-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 3
[patent_no_of_words] => 12339
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 120
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18632908
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/632908 | PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS | Apr 10, 2024 | Issued |